Article
AbbVie Reports EC Approval Of RINVOQ For Treatment Of Giant Cell Arteritis - Quick Facts
Neutral
0.0
−100 Bearish
0
+100 Bullish
(RTTNews) - AbbVie (ABBV) announced that the European Commission granted marketing authorization to RINVOQ for the treatment of giant cell arteritis in adult patients. RINVOQ is the first and only oral JAK inhibitor approved in the EU, as well as Iceland, Liechtenstein and Norway
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Source
NASDAQ Markets
Published
Apr 8, 2025 · 6:13 am
Article ID
42783896172224269626
Original URL
Open source
Sentiment Signal
Neutral
0.0
−100Neutral+100
More Like This